Results 121 to 130 of about 3,373 (135)

Economic burden of generalized pustular psoriasis and palmoplantar pustulosis in the United States

Current Medical Research and Opinion, 2021
Maya L Hanna, David Singer
exaly  

Treatments and outcomes of generalized pustular psoriasis: A cohort of 1516 patients in a nationwide inpatient database in Japan

Journal of the American Academy of Dermatology, 2022
Hideaki Miyachi, Takaaki Konishi, Ryosuke Kumazawa   +2 more
exaly  

Spesolimab, an interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis

Expert Review of Clinical Immunology, 2023
A D Burden
exaly  

Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion

Expert Review of Clinical Immunology, 2022
Hervé Bachelez, J N W N Barker, A D Burden   +2 more
exaly  

Successful treatment of paediatric generalized pustular psoriasis with secukinumab: a case series

Journal of Dermatological Treatment, 2022
Henrietta Albela
exaly  

<p>Diagnosis and screening of patients with generalized pustular psoriasis</p>

Psoriasis: Targets and Therapy, 2019
Karen Ly, Kristen M Beck, Mary Patricia Smith   +2 more
exaly  

An update on generalized pustular psoriasis

Expert Review of Clinical Immunology, 2019
Melinda Gooderham
exaly  

Interleukin-36–Receptor Antagonist Deficiency and Generalized Pustular Psoriasis

New England Journal of Medicine, 2011
Blair R Renshaw, Anne Puel, C Cluzeau
exaly  

Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis

New England Journal of Medicine, 2019
Hervé Bachelez, Siew Eng Choon, A D Burden   +2 more
exaly  

IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis

Journal of Allergy and Clinical Immunology, 2017
Andrew Johnston, Xianying Xing, Zhiqiang Yin   +2 more
exaly